Yi-Ru Pan

10PUBLICATIONS
13CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer cell biologyCancer therapy (excl. chemotherapy and radiation therapy)Chemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Feb 07, 2026
Ataxia-telangiectasia mutated kinase inhibition overcomes gemcitabine resistance in intrahepatic cholangiocarcinoma via DNA ligase I-dependent repair vulnerability.

Sheng-Hsuan Lin, Yi-Ru Pan, Tsai-Hsien Hung

|Nov 22, 2025
PufA drives cholangiocarcinoma progression via NFκB signaling activation: a novel therapeutic target.

Chiao-Ping Chen, Tsai-Hsien Hung, Yenlin Huang

|Dec 06, 2023
PLK1 and its substrate MISP facilitate intrahepatic cholangiocarcinoma progression by promoting lymphatic invasion and impairing E-cadherin adherens junctions.

Yi-Ru Pan, Joseph Chieh-Yu Lai, Wen-Kuan Huang

|Aug 27, 2021
Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway.

Shin-Yi Chung, Yi-Ping Hung, Yi-Ru Pan

|Dec 01, 2020
Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model.

Yi-Ru Pan, Chiao-En Wu, Ming-Huang Chen

|Nov 13, 2020
ATM Inhibitor Suppresses Gemcitabine-Resistant BTC Growth in a Polymerase θ Deficiency-Dependent Manner.

Yi-Ru Pan, Chiao-En Wu, Chun-Nan Yeh

Pageof 2

Frequent Collaborators

6 joint publications

Chiao-En Wu

4 joint publications

Chun-Nan Yeh

2 joint publications

Wen-Kuan Huang

1 joint publications

Muh-Hwa Yang